Delivery of SIRT1 by Cancer-associated Adipocyte-derived Extracellular Vesicles Regulates Immune Response and Tumorigenesis of Ovarian Cancer Cells

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2023 Jun 13

PMID 37311988

Authors

Qingling Zheng

Xiuluan Du

Jin Zhang

Yanxiang Liu

Weijia Dong

Xin Dai

DongHua Gu

Affiliations

Soon will be listed here.

Abstract

Purpose: This study intends to investigate the possible molecular mechanism of immune response and tumorigenesis in ovarian cancer cells, mediated by sirtuin 1 (SIRT1)-containing extracellular vesicles (EVs) derived from cancer-associated adipocytes (CAAs) (CAA-EVs).

Methods: Differentially expressed genes in EVs from CAAs were screened by RNA transcriptome sequencing, and the downstream pathway was predicted in silico. The binding between SIRT1 and CD24 was investigated by luciferase activity and ChIP-PCR assays. EVs were extracted from human ovarian cancer tissue-isolated CAAs, and the internalization of CCA-EVs by ovarian cancer cells was characterized. The ovarian cancer cell line was injected into mice to establish an animal model. Flow cytometry was performed to analyze the proportions of M1 and M2 macrophages, CD8 T, T-reg, and CD4 T cells. TUNEL staining was used to detect cell apoptosis in the mouse tumor tissues. ELISA detection was performed on immune-related factors in the serum of mice.

Results: CAA-EVs could deliver SIRT1 to ovarian cancer cells, thereby affecting the immune response of ovarian cancer cells in vitro and promoting tumorigenesis in vivo. SIRT1 could transcriptionally activate the expression of CD24, and CD24 could up-regulate Siglec-10 expression. CAA-EVs-SIRT1 activated the CD24/Siglec-10 axis and promoted CD8 T cell apoptosis, thereby promoting tumorigenesis in mice.

Conclusion: CAA-EVs-mediated transfer of SIRT1 regulates the CD24/Siglec-10 axis to curb immune response and promote tumorigenesis of ovarian cancer cells.

Citing Articles

Glycan diversity in ovarian cancer: Unraveling the immune interplay and therapeutic prospects.

Wolters-Eisfeld G, Oliveira-Ferrer L Semin Immunopathol. 2024; 46(6):16.

PMID: 39432076 PMC: 11493797. DOI: 10.1007/s00281-024-01025-6.

The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy.

Tang Y, Ju W, Liu Y, Deng Q Front Pharmacol. 2024; 15:1469830.

PMID: 39403142 PMC: 11471651. DOI: 10.3389/fphar.2024.1469830.

SIRT1 silencing ameliorates malignancy of non-small cell lung cancer via activating FOXO1.

Chen J, Chen K, Zhang S, Huang X Sci Rep. 2024; 14(1):19948.

PMID: 39198693 PMC: 11358480. DOI: 10.1038/s41598-024-70970-x.

Cancer-associated adipocytes in the ovarian cancer microenvironment.

Cai Q, Yang J, Shen H, Xu W Am J Cancer Res. 2024; 14(7):3259-3279.

PMID: 39113876 PMC: 11301307. DOI: 10.62347/XZRI9189.

Pan-cancer analysis of super-enhancer-induced LINC00862 and validation as a SIRT1-promoting factor in cervical cancer and gastric cancer.

Liu S, Wang Z, Hu L, Ye C, Zhang X, Zhu Z Transl Oncol. 2024; 45:101982.

PMID: 38718436 PMC: 11097084. DOI: 10.1016/j.tranon.2024.101982.

References

Maoz A, Matsuo K, Ciccone M, Matsuzaki S, Klar M, Roman L . Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord-Stromal Tumors: A Contemporary Review. Cancers (Basel). 2020; 12(6). PMC: 7353025. DOI: 10.3390/cancers12061398. View

Zilovic D, ciurliene R, Sabaliauskaite R, Jarmalaite S . Future Screening Prospects for Ovarian Cancer. Cancers (Basel). 2021; 13(15). PMC: 8345180. DOI: 10.3390/cancers13153840. View

Lheureux S, Gourley C, Vergote I, Oza A . Epithelial ovarian cancer. Lancet. 2019; 393(10177):1240-1253. DOI: 10.1016/S0140-6736(18)32552-2. View

Osborne L, Dhanji S, Snow J, Priatel J, Ma M, Miners M . Impaired CD8 T cell memory and CD4 T cell primary responses in IL-7R alpha mutant mice. J Exp Med. 2007; 204(3):619-31. PMC: 2137912. DOI: 10.1084/jem.20061871. View

Pekalski M, Rubio Garcia A, Ferreira R, Rainbow D, Smyth D, Mashar M . Neonatal and adult recent thymic emigrants produce IL-8 and express complement receptors CR1 and CR2. JCI Insight. 2017; 2(16). PMC: 5621870. DOI: 10.1172/jci.insight.93739. View

Starzer A, Preusser M, Berghoff A . Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. Ther Adv Med Oncol. 2022; 14:17588359221096219. PMC: 9058458. DOI: 10.1177/17588359221096219. View

van Niel G, DAngelo G, Raposo G . Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018; 19(4):213-228. DOI: 10.1038/nrm.2017.125. View

Munteanu R, Onaciu A, Moldovan C, Zimta A, Gulei D, Paradiso A . Adipocyte-Based Cell Therapy in Oncology: The Role of Cancer-Associated Adipocytes and Their Reinterpretation as Delivery Platforms. Pharmaceutics. 2020; 12(5). PMC: 7284545. DOI: 10.3390/pharmaceutics12050402. View

Tian W, Lei N, Zhou J, Chen M, Guo R, Qin B . Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion. Cell Death Dis. 2022; 13(1):64. PMC: 8766448. DOI: 10.1038/s41419-022-04510-8. View

10.

Shen P, Deng X, Chen Z, Ba X, Qin K, Huang Y . SIRT1: A Potential Therapeutic Target in Autoimmune Diseases. Front Immunol. 2021; 12:779177. PMC: 8650132. DOI: 10.3389/fimmu.2021.779177. View

11.

Lin Z, Fang D . The Roles of SIRT1 in Cancer. Genes Cancer. 2013; 4(3-4):97-104. PMC: 3764469. DOI: 10.1177/1947601912475079. View

12.

Zhang X, Chen J, Sun L, Xu Y . SIRT1 deacetylates KLF4 to activate Claudin-5 transcription in ovarian cancer cells. J Cell Biochem. 2017; 119(2):2418-2426. DOI: 10.1002/jcb.26404. View

13.

Duan J, Yin M, Shao Y, Zheng J, Nie S . Puerarin induces platinum-resistant epithelial ovarian cancer cell apoptosis by targeting SIRT1. J Int Med Res. 2021; 49(9):3000605211040762. PMC: 8489779. DOI: 10.1177/03000605211040762. View

14.

Wang T, Chern E, Hsu C, Tseng K, Chao H . SIRT1-Mediated Expression of CD24 and Epigenetic Suppression of Novel Tumor Suppressor miR-1185-1 Increases Colorectal Cancer Stemness. Cancer Res. 2020; 80(23):5257-5269. DOI: 10.1158/0008-5472.CAN-19-3188. View

15.

Barkal A, Brewer R, Markovic M, Kowarsky M, Barkal S, Zaro B . CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019; 572(7769):392-396. PMC: 6697206. DOI: 10.1038/s41586-019-1456-0. View

16.

Crocker P, Paulson J, Varki A . Siglecs and their roles in the immune system. Nat Rev Immunol. 2007; 7(4):255-66. DOI: 10.1038/nri2056. View

17.

Abram C, Lowell C . Shp1 function in myeloid cells. J Leukoc Biol. 2017; 102(3):657-675. PMC: 5557645. DOI: 10.1189/jlb.2MR0317-105R. View

18.

Li Y, Zhou J, Zhuo Q, Zhang J, Xie J, Han S . Malignant ascite-derived extracellular vesicles inhibit T cell activity by upregulating Siglec-10 expression. Cancer Manag Res. 2019; 11:7123-7134. PMC: 6681125. DOI: 10.2147/CMAR.S210568. View

19.

Lee J, Hong B, Ryu H, Lee H, Lee M, Park I . Transition into inflammatory cancer-associated adipocytes in breast cancer microenvironment requires microRNA regulatory mechanism. PLoS One. 2017; 12(3):e0174126. PMC: 5363867. DOI: 10.1371/journal.pone.0174126. View

20.

Dai X, Xie Y, Dong M . Cancer-associated fibroblasts derived extracellular vesicles promote angiogenesis of colorectal adenocarcinoma cells through miR-135b-5p/FOXO1 axis. Cancer Biol Ther. 2022; 23(1):76-88. PMC: 8812748. DOI: 10.1080/15384047.2021.2017222. View